FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933622020> ?p ?o ?g. }

• W2933622020 endingPage "e000876" @default.
• W2933622020 startingPage "e000876" @default.
• W2933622020 abstract "Objective To investigate the efficacy, safety and immunogenicity of PF-06438179/GP1111 (PF-SZ-IFX) compared with European reference infliximab (Remicade ® ; ref-IFX) in patients with moderate-to-severe, active rheumatoid arthritis after continued long-term use of PF-SZ-IFX, and in patients who were switched from ref-IFX to PF-SZ-IFX. Methods REFLECTIONS B537-02 was a double-blind, active-controlled, multinational study in which patients (N=650) were initially randomised to PF-SZ-IFX or ref-IFX for 30 weeks (treatment period [TP] 1). During weeks 30–54 (TP2), the PF-SZ-IFX group (n=280) continued treatment with PF-SZ-IFX (PF-SZ-IFX/PF-SZ-IFX) and patients in the ref-IFX group (n=286) were rerandomised (1:1) to continue ref-IFX (ref-IFX/ref-IFX) (n=143) or switch to PF-SZ-IFX (ref-IFX/PF-SZ-IFX) (n=143) for a further 24 weeks. Efficacy, safety, immunogenicity and pharmacokinetics were evaluated. Results During TP2, patients in all three treatment groups continued to maintain comparable treatment response. At week 54, the American College of Rheumatology (ACR20) response rates were 71.1% (PF-SZ-IFX/PF-SZ-IFX), 64.3% (ref-IFX/ref-IFX) and 70.6% (ref-IFX/PF-SZ-IFX). Observations for other endpoints, including ACR50/70, Disease Activity Score in 28 Joints Based on High-Sensitivity C Reactive Protein(DAS28-CRP) remission, and mean change in DAS28-CRP and Health Assessment Questionnaire-Disability Index, were also comparable. Treatment-emergent adverse events were reported in 36.8% (PF-SZ-IFX/PF-SZ-IFX), 33.6% (ref-IFX/ref-IFX) and 37.8% (ref-IFX/PF-SZ-IFX) of patients; there were no clinically meaningful differences in the safety profiles between groups. The percentage of patients who were antidrug antibody-positive was generally stable through the treatment period and comparable overall between the PF-SZ-IFX/PF-SZ-IFX (52.1%; neutralising: 80.8%), ref-IFX/ref-IFX (60.1%; neutralising: 84.9%) and ref-IFX/PF-SZ-IFX (58.0%; neutralising 78.3%) groups. Conclusions The similar efficacy, safety and immunogenicity of PF-SZ-IFX compared with ref-IFX were maintained for up to 54 weeks and were not affected by blinded treatment switch from ref-IFX to PF-SZ-IFX at week 30. Trial registration number NCT02222493 ." @default.
• W2933622020 created "2019-04-11" @default.
• W2933622020 creator A5000248389 @default.
• W2933622020 creator A5019345740 @default.
• W2933622020 creator A5022988657 @default.
• W2933622020 creator A5030599616 @default.
• W2933622020 creator A5041297167 @default.
• W2933622020 creator A5047604961 @default.
• W2933622020 creator A5053204257 @default.
• W2933622020 creator A5057197585 @default.
• W2933622020 creator A5057538503 @default.
• W2933622020 creator A5058629132 @default.
• W2933622020 creator A5066439668 @default.
• W2933622020 creator A5078506443 @default.
• W2933622020 creator A5082702151 @default.
• W2933622020 date "2019-03-01" @default.
• W2933622020 modified "2023-10-12" @default.
• W2933622020 title "Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54" @default.
• W2933622020 cites W1176283365 @default.
• W2933622020 cites W1251997985 @default.
• W2933622020 cites W2005869754 @default.
• W2933622020 cites W2085740292 @default.
• W2933622020 cites W2097564087 @default.
• W2933622020 cites W2314763045 @default.
• W2933622020 cites W2342464058 @default.
• W2933622020 cites W2407658018 @default.
• W2933622020 cites W2517740188 @default.
• W2933622020 cites W2545293585 @default.
• W2933622020 cites W2584947097 @default.
• W2933622020 cites W2613299853 @default.
• W2933622020 cites W2736727076 @default.
• W2933622020 cites W2753254104 @default.
• W2933622020 cites W2753958839 @default.
• W2933622020 cites W2767179430 @default.
• W2933622020 cites W2771792812 @default.
• W2933622020 cites W2775519512 @default.
• W2933622020 cites W2794295970 @default.
• W2933622020 cites W2803249284 @default.
• W2933622020 cites W2806623595 @default.
• W2933622020 cites W2883657995 @default.
• W2933622020 cites W2883934894 @default.
• W2933622020 cites W2894239243 @default.
• W2933622020 cites W2898893516 @default.
• W2933622020 cites W2900361267 @default.
• W2933622020 cites W2908795744 @default.
• W2933622020 cites W2908940144 @default.
• W2933622020 cites W2910600549 @default.
• W2933622020 doi "https://doi.org/10.1136/rmdopen-2018-000876" @default.
• W2933622020 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6446180" @default.
• W2933622020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30997153" @default.
• W2933622020 hasPublicationYear "2019" @default.
• W2933622020 type Work @default.
• W2933622020 sameAs 2933622020 @default.
• W2933622020 citedByCount "15" @default.
• W2933622020 countsByYear W29336220202019 @default.
• W2933622020 countsByYear W29336220202020 @default.
• W2933622020 countsByYear W29336220202021 @default.
• W2933622020 countsByYear W29336220202022 @default.
• W2933622020 crossrefType "journal-article" @default.
• W2933622020 hasAuthorship W2933622020A5000248389 @default.
• W2933622020 hasAuthorship W2933622020A5019345740 @default.
• W2933622020 hasAuthorship W2933622020A5022988657 @default.
• W2933622020 hasAuthorship W2933622020A5030599616 @default.
• W2933622020 hasAuthorship W2933622020A5041297167 @default.
• W2933622020 hasAuthorship W2933622020A5047604961 @default.
• W2933622020 hasAuthorship W2933622020A5053204257 @default.
• W2933622020 hasAuthorship W2933622020A5057197585 @default.
• W2933622020 hasAuthorship W2933622020A5057538503 @default.
• W2933622020 hasAuthorship W2933622020A5058629132 @default.
• W2933622020 hasAuthorship W2933622020A5066439668 @default.
• W2933622020 hasAuthorship W2933622020A5078506443 @default.
• W2933622020 hasAuthorship W2933622020A5082702151 @default.
• W2933622020 hasBestOaLocation W29336220201 @default.
• W2933622020 hasConcept C112705442 @default.
• W2933622020 hasConcept C126322002 @default.
• W2933622020 hasConcept C141071460 @default.
• W2933622020 hasConcept C159654299 @default.
• W2933622020 hasConcept C197934379 @default.
• W2933622020 hasConcept C198451711 @default.
• W2933622020 hasConcept C203014093 @default.
• W2933622020 hasConcept C2777138892 @default.
• W2933622020 hasConcept C2777575956 @default.
• W2933622020 hasConcept C2779134260 @default.
• W2933622020 hasConcept C2780868878 @default.
• W2933622020 hasConcept C59491497 @default.
• W2933622020 hasConcept C71924100 @default.
• W2933622020 hasConcept C90924648 @default.
• W2933622020 hasConceptScore W2933622020C112705442 @default.
• W2933622020 hasConceptScore W2933622020C126322002 @default.
• W2933622020 hasConceptScore W2933622020C141071460 @default.
• W2933622020 hasConceptScore W2933622020C159654299 @default.
• W2933622020 hasConceptScore W2933622020C197934379 @default.
• W2933622020 hasConceptScore W2933622020C198451711 @default.
• W2933622020 hasConceptScore W2933622020C203014093 @default.
• W2933622020 hasConceptScore W2933622020C2777138892 @default.
• W2933622020 hasConceptScore W2933622020C2777575956 @default.
• W2933622020 hasConceptScore W2933622020C2779134260 @default.
• W2933622020 hasConceptScore W2933622020C2780868878 @default.

• next